+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Anti Tumour Necrosis Factor"

From
From
From
From
From
Ulcerative Colitis Epidemiology Analysis and Forecast, 2021-2031 - Product Thumbnail Image

Ulcerative Colitis Epidemiology Analysis and Forecast, 2021-2031

  • Report
  • February 2023
  • 48 Pages
  • Global
From
From
CD40 Ligand - Pipeline Review, H2 2019 - Product Thumbnail Image

CD40 Ligand - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 74 Pages
  • Global
From
From
Loading Indicator

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications. The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more